Bain Capital and Biotech

Selected healthcare news for the capital firm - Bain Capital, and the healthcare topic - Biotech. We have 38 shared news items for this connection to-date.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source Relevant Snippet
12/10/2021 Freenome Lands $300 Million Series D for Early Cancer Detection SOUTH SAN FRANCISCO ‚Ai Freenome, a privately held biotech company, has landed a Series D funding of $300 million. This brings the company‚Aos total financing to over $800 million since the company was founded in 2014.This round was led by Perceptive Advisors and RA Capital Management, joined by existing investors including a16z Life Sciences Growth Fund, the American Cancer Society‚Aos BrightEdge Ventures, Artis Ventures, Bain Capital Life ...
12/7/2021 Freenome Raises $300M in Series D Financing to Advance Multiomics Platform for Early Cancer Detection PR Newswire SOUTH SAN FRANCISCO, Calif. , Freenome, a privately held biotech company, today announced a Series D funding of $300 million . This brings the company's total financing to over $800 million since the company was founded in 2014.This round of financing was led by investors Perceptive Advisors and RA Capital Management, joined by existing investors including a16z Life Sciences Growth Fund, the American Cancer Society's BrightEdge Ventures, Artis Ventures, Bain Capital ...
8/25/2021 Bain Capital seals $2.5bn Hugel sale to CBC Group-led consortium Bain Capital has sold its stake in Korean cosmetic pharmaceutical company Hugel to a consortium led by CBC Group to give the business a $2.5bn valuation. CBC, Asia‚Aos largest healthcare-dedicated investment firm headquartered ... stage growth and buyout investment opportunities in China including pharmaceutical, biotech, medical technology and healthcare services. Michael Keyoung, head of North America and Korea at CBC, said, ‚AuThis marks the beginning of CBC‚Aos journey ...
8/17/2021 $1.9bn raised for Bain Capital's life sciences fund Boston Globe INVESTING$1.9 billion raised for Bain Capital‚Aos life sciences fund Bain Capital‚Aos life sciences arm has just finished raising $1.9 billion for its third investment fund, including $300 million from current and former partners of the Boston-based private equity firm, and it has begun searching for drug, biotech, and medical device companies where it can invest the money. The types of companies that the 16-person team ...
8/17/2021 Going big: Bain reels in $1.9B for more mammoth biotech bets | FierceBiotech FierceBiotech Bain Capital‚Aos time in life science investing has been defined by big numbers: $720 million for its first fund, $1.1 billion for the second fund, $350 million for a single bet on Pfizer‚Aos ... a gap in the market for a particularly deep-pocketed biotech investor capable of backing pre-IPO crossover rounds, helping more advanced businesses build out commercial infrastructure and giving Big Pharma companies a way to ...
8/17/2021 Private equity dives deeper into biotech with nearly $2B Bain fundraise | BioPharma Dive Dive Brief: Boston-based investment firm Bain Capital has raised $1.9 billion in a new fund directed at pharmaceutical, biotechnology and medical device companies. The news was first reported by Endpoints News. This latest life sciences fund, Bain's third, includes $300 million from current and former partners, according to a spokesperson. In 2017, Bain closed its first life sciences fund, earmarking $720 million for investments. Two years later, the firm ...
8/7/2021 Translate Bio, Nuvalent See Activist Action | Barron's ... 29 through Aug. 4, 2021. Source: InsiderScore.comActivist Holdings Translate Bio (TBIO)Baupost Group reported a 24% interest in the biotech, equal to 18,044,239 shares. On Aug. 4, Baupost revealed that it had entered into ... now awaits shareholder and regulatory approval.Original Filings Nuvalent (NUVL)Bain Capital Life Sciences initiated a position in the pre-clinical-stage biopharmaceutical firm of 3,428,014 shares, an 8% interest. Of those Nuvalent shares, 735,000 ...
7/20/2021 Amylyx raises $135M to gear up for potential Canadian launch of ALS drug | FierceBiotech FierceBiotech ... biotech raked in the oversubscribed series C Tuesday to support the clinical development and launch plans, pending a Canadian green light for the amyotrophic lateral sclerosis (ALS) treatment. The novel combination of compounds called AMX0035 was found to slow the progression of ALS in a phase 2/3 study presented last September.Viking Global Investors led Tuesday's financing round, with participation from Bain Capital Life Sciences, Perceptive Advisors and about a ...
7/20/2021 Amylyx, faced with longer FDA path for promising ALS drug, gets major cash infusion | BioPharma Dive Dive Brief: Amylyx Pharmaceuticals, a small biotech developing a promising experimental medicine for ALS, has raised $135 million from a group of venture capital firms to fund late-stage clinical testing and preparations for a ... 135 million Series C, which came from Viking Global Investors, Bain Capital and several other firms, is more than five times what Amylyx raised in two prior venture funding rounds in 2016 and 2020. Previous ...
4/13/2021 Bain doubles down on Tony Coles‚Äô quest to get a late-stage Parkinson's drug through to market ‚Äì Endpoints News Cerevel Therapeutics had a charmed start to its life with the backing of financial giant Bain Capital and a clutch of former Pfizer assets to work with. Now, extending its relationship with Bain, Cerevel has ... up to $531 million in future milestones at stake, the biotech said Tuesday.Keep reading Endpoints with a free subscription Unlock this story instantly and join 107,200+ biopharma pros reading Endpoints daily ‚Ai and it's ...
3/5/2021 From vaccines to apps for truck drivers, Lincoln startups mark big year for investments ... is now a mature company.If you consider Hudl a startup, then the $120 million it raised last year from Bain Capital dwarfs any capital raised in the history not just of Lincoln startups but ... 20 million apiece just a week apart last January. Lincoln biotech company gets $20 million venture capital investmentBoth have since validated those investments by taking big steps forward. Adjuvance, which makes an agent called ...
2/28/2021 Directions 2021: From vaccines to apps for truck drivers, Lincoln startups mark big year for investments ... is now a mature company.If you consider Hudl a startup, then the $120 million it raised last year from Bain Capital dwarfs any capital raised in the history not just of Lincoln startups but ... 20 million apiece just a week apart last January. Lincoln biotech company gets $20 million venture capital investmentBoth have since validated those investments by taking big steps forward. Adjuvance, which makes an agent called ...
9/28/2020 IPOs this week : Sept. 28 - Oct. 2, 20 (wk 40) ... Acceleron Pharma (XLRN) Adam Street Partners ADAP ADCT Adeptus Health (ADPT) ADIL Admeld ADNT ADPT ADS Tactical (ADSI) ADT Aduro BioTech (ADRO) Advanced Drainage Systems (WMS) Aerie Pharmaceuticals (AERI) Aerohive Networks (HIVE) AFH AFIB AFYA ... AVO AVTR AXLA Axovant Sciences (AXON) AYLA AZEK AZRE BABA Bain Capital bankruptcies BATS Bazaar Voice (BV) BBIO BC Partners BCDA BCEL BCSF BCYC BDTX BE BEAM BEDU BEER Bellicum Pharmaceuticals (BLCM) Benchmark Capital Bermuda ...
8/31/2020 54 Biggest Movers From Friday | Benzinga Benzinga ... on Friday after climbing 14% on Thursday. The company reported better-than-expected FY20 preliminary results on Monday morning. Edesa Biotech, Inc. (NASDAQ: EDSA ) shares gained 40.3% to close at $8.15. Edesa Biotech, earlier during ... next CEO. Nutanix also reported a $750 million investment from Bain Capital Private Equity. Just Energy Group Inc. (NYSE: JE ) shares jumped 26.2% to close at $0.3895 on Friday after the company announced stakeholder approval ...
8/17/2020 IPOs this week : August 17 - 21, 20 (wk 34) ... Acceleron Pharma (XLRN) Adam Street Partners ADAP ADCT Adeptus Health (ADPT) ADIL Admeld ADNT ADPT ADS Tactical (ADSI) ADT Aduro BioTech (ADRO) Advanced Drainage Systems (WMS) Aerie Pharmaceuticals (AERI) Aerohive Networks (HIVE) AFH AFYA Agile ... AVLR AVTR AXLA Axovant Sciences (AXON) AYLA AZEK AZRE BABA Bain Capital bankruptcies Baozun (BZUN) BATS Bazaar Voice (BV) BBIO BC Partners BCDA BCEL BCSF BCYC BDTX BE BEAM BEDU BEER Bellicum Pharmaceuticals (BLCM) Benchmark ...
7/31/2020 Cerevel to raise $445M, hit Wall Street via blank check company | FierceBiotech FierceBiotech Unlike a traditional biotech built around a lab discovery, Cerevel Therapeutics got a “unique” start : with $350 million from Bain Capital and a clutch of central nervous system programs from Pfizer. Now, it’s continuing its unorthodox streak as it taps the public markets. The company is going public by merging with a public special purpose acquisition company (SPAC) set up by Perceptive Advisors. Also called blank check companies, SPACs are ...
6/15/2020 IPOs this week : June 15 - 19, 20 (wk 24) ... Acceleron Pharma (XLRN) Adam Street Partners ADAP ADCT Adeptus Health (ADPT) ADIL Admeld ADNT ADPT ADS Tactical (ADSI) ADT Aduro BioTech (ADRO) Advanced Drainage Systems (WMS) Aerie Pharmaceuticals (AERI) Aerohive Networks (HIVE) AFH AFYA Agile ... AVH) AVLR AVTR AXLA Axovant Sciences (AXON) AYLA AZRE BABA Bain Capital bankruptcies Baozun (BZUN) BATS Bazaar Voice (BV) BBIO BC Partners BCDA BCEL BCSF BCYC BDTX BE BEDU BEER Bellicum Pharmaceuticals (BLCM) Benchmark Capital ...
11/27/2019 Global RNAi Therapeutics Market 2019-2030: Focus on siRNA, miRNA, shRNA and DNA PR Newswire ... Biotechnology Avidity Biosciences Axovant Gene Therapies Bain Capital Life Sciences Benitec Biopharma Biogen Biomics Biotechnologies (a GE Unit) Bioneer BioNTech Biosettia BioSpring BioXcel Therapeutics bluebird bio Boehringer Ingelheim Boston Children's Hospital Boulder Ventures Brace Pharma Capital Bristol- Myers Squibb Broad Institute Broadview Ventures Calimmune CAMP4 Therapeutics C-Bridge Capital Cell Signaling Technology Cellecta Celsion Cenix BioScience Charoen Pokphand Group Children's Hospital of Philadelphia Circuit Therapeutics City of Hope National Medical ...
11/15/2019 Viva Biotech Partnership Summit Successfully Launched in Shanghai | Markets Insider Business Insider SHANGHAI , Nov. 15, 2019 /PRNewswire/ -- 2019 Viva Biotech Partnership Summit (the "Summit") was successfully launched on 8 November 2019 in Pudong, Shanghai , themed "Innovation Partnership Growth". Founders from over 30 global innovative and biopharmaceutical companies ... Assistant President of Fosun Group ; Jia Zhu , Managing Director of Bain Capital ; Shixiong Gan , Founder of WisdoMont ; Yijing Xie , Managing Director of China Renaissance ; Denise Chen , Managing Partner of GTJA Investment ; John Zhu , Partner of ...
11/15/2019 Viva Biotech Partnership Summit Successfully Launched in Shanghai PR Newswire SHANGHAI , Nov. 15, 2019 /PRNewswire/ -- 2019 Viva Biotech Partnership Summit (the "Summit") was successfully launched on 8 November 2019 in Pudong, Shanghai , themed "Innovation Partnership Growth". Founders from over 30 global innovative and biopharmaceutical companies ... Assistant President of Fosun Group ; Jia Zhu , Managing Director of Bain Capital ; Shixiong Gan , Founder of WisdoMont ; Yijing Xie , Managing Director of China Renaissance ; Denise Chen , Managing Partner of GTJA Investment ; John Zhu , Partner of ...
11/15/2019 Viva Biotech Partnership Summit Successfully Launched in Shanghai | Benzinga SHANGHAI , Nov. 15, 2019 /PRNewswire/ -- 2019 Viva Biotech Partnership Summit (the "Summit") was successfully launched on 8 November 2019 in Pudong, Shanghai , themed "Innovation Partnership Growth". Founders from over 30 global innovative and biopharmaceutical companies ... Assistant President of Fosun Group ; Jia Zhu , Managing Director of Bain Capital ; Shixiong Gan , Founder of WisdoMont ; Yijing Xie , Managing Director of China Renaissance ; Denise Chen , Managing Partner of GTJA Investment ; John Zhu , Partner of ...
11/15/2019 Viva Biotech Partnership Summit Successfully Launched in Shanghai | The Wapakoneta Daily News SHANGHAI , Nov. 15, 2019 /PRNewswire/ -- 2019 Viva Biotech Partnership Summit (the "Summit") was successfully launched on 8 November 2019 in Pudong, Shanghai , themed "Innovation Partnership Growth". Founders from over 30 global innovative and biopharmaceutical companies ... Assistant President of Fosun Group ; Jia Zhu , Managing Director of Bain Capital ; Shixiong Gan , Founder of WisdoMont ; Yijing Xie , Managing Director of China Renaissance ; Denise Chen , Managing Partner of GTJA Investment ; John Zhu , Partner of ...
11/13/2019 Greenberg Traurig’s David J. Dykeman Co-Chairs CJP Health Professions Annual Breakfast PRWeb ... biotech, pharma, healthcare, medtech, and diagnostics industries to strengthen business relationships within the Greater Boston Jewish community. Keynote speaker Adam M. Koppel, M.D., Ph.D., Managing Director, Bain Capital Life Sciences, will discuss, “How Innovation is Improving Delivery of Medical Care — Creating Value for Patients and Investors.” In addition, attendees will honor Beverly Siegal, M.D., M.P.H. with The Lewis H. Millender Community of Excellence Award. Prior to the breakfast, Dykeman, who ...
10/30/2019 Global Cell Encapsulation Research Report 2019-2030 PR Newswire ... and optimistic tracks of the market's evolution. Companies Mentioned 24Haymarket 3P Biopharmaceuticals 4D Pharma Aarhus University Hospital Acer Therapeutics Activartis Biotech Activate Immunotherapy Adaptimmune Adicet Bio ADIRA Aduro Biotech Advent Bioservices Agency for Science, Technology ... Austrianova Singapore Autolus AVAX Technologies Axil Scientific Azellon Cell Therapeutics Bain Capital Life Sciences Bascom Palmer Eye Institute Basic Pharma Batavia Bioservices Bavarian Nordic Baxalta Baxter International Baylor College of Medicine BBS Nanotechnology Beijing Biohealthcare ...
10/28/2019 CDPQ invests in Piramal Enterprises PE Hub ... pension funds such as CPPIB, APG and Ivanhoe Cambridge. The division has also launched a Distressed Asset Investing platform with Bain Capital Credit – IndiaRF that will invest in equity and/or debt in assets across ... insight products and consulting services to the world’s leading pharma, biotech and medical technology companies, enabling them to make informed business decisions. PEL is listed on the BSE Limited and the National Stock Exchange of ...